Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EpCAM CAR-T in Advanced Solid Tumors
NCT02915445Phase 1Active, not recruiting
- Sponsor
- Sichuan University
- Start
- Jul 2016
- Primary completion
- Jul 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of EpCAM CAR-T in nasopharyngeal carcinoma (NPC), breast cancer, gastric cancer (GC) and 1 more, sponsored by Sichuan University. Primary endpoint: Number of participants with treatment-related adverse events/dose limiting toxicity at 6 weeks. Started Jul 2016; status: active, not recruiting.
02
Drugs
EpCAM CAR-T
03
Conditions
nasopharyngeal carcinoma (NPC)breast cancergastric cancer (GC)solid tumor
Beyond the preview
Go deeper on NCT02915445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02915445.